Roy Strowd to Antineoplastic Agents
This is a "connection" page, showing publications Roy Strowd has written about Antineoplastic Agents.
Connection Strength
2.021
-
Renfrow JJ, Soike MH, West JL, Ramkissoon SH, Metheny-Barlow L, Mott RT, Kittel CA, D'Agostino RB, Tatter SB, Laxton AW, Frenkel MB, Hawkins GA, Herpai D, Sanders S, Sarkaria JN, Lesser GJ, Debinski W, Strowd RE. Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. Sci Rep. 2020 09 16; 10(1):15195.
Score: 0.536
-
Lycan TW, Hsu FC, Ahn CS, Thomas A, Walker FO, Sangueza OP, Shiozawa Y, Park SH, Peters CM, Romero-Sandoval EA, Melin SA, Sorscher S, Ansley K, Lesser GJ, Cartwright MS, Strowd RE. Neuromuscular ultrasound for taxane peripheral neuropathy in breast cancer. Muscle Nerve. 2020 05; 61(5):587-594.
Score: 0.515
-
Mancone S, Lycan T, Ahmed T, Topaloglu U, Dothard A, Petty WJ, Strowd RE. Severe neurologic complications of immune checkpoint inhibitors: a single-center review. J Neurol. 2018 Jul; 265(7):1636-1642.
Score: 0.455
-
Strowd RE, Abuali IA, Grossman SA. Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma. CNS Oncol. 2015; 4(3):131-5.
Score: 0.368
-
Pennypacker SD, Fonseca MM, Morgan JW, Dougherty PM, Cubillos-Ruiz JR, Strowd RE, Romero-Sandoval EA. Methods and protocols for chemotherapy-induced peripheral neuropathy (CIPN) mouse models using paclitaxel. Methods Cell Biol. 2022; 168:277-298.
Score: 0.147